Citi Starts Keryx Biopharmaceuticals (KERX) at Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Brean Capital Reiterates Buy on Keryx Biopharma (KERX) on Potential Catalysts and Improving Sales Dynamics
September 4, 2015 9:02 AM EDTBrean Capital reiterated a Buy rating and $22.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX) on potential catalysts and improving sales dynamics. Keryx's 50% salesforce increase should make a noticeable impact on revenue, on which analyst Jonathan Aschoff says Keryx will be judged more than its bottom line, for the foreseeable future.
Aschoff commented, "We view the recent Keryx selloff as overdone, especially when considering several factors that we believe have led to a... More
